SK Bioscience Co (XKRX:302440) Net Issuance of Debt

: ₩-83,554 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. SK Bioscience Co's net issuance of debt for the three months ended in Dec. 2023 was ₩0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-83,554 Mil.

SK Bioscience Co Net Issuance of Debt Historical Data

The historical data trend for SK Bioscience Co's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

-23,435.49

-1,237.37

-22,410.37

-15,453.89

-83,553.99

SK Bioscience Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Debt																-5,995.56	-45,550.00	-38,004.00	-	-

SK Bioscience Co Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-83,554 Mil.

SK Bioscience Co Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co (XKRX:302440) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines